People Using GLP-1s, Like Ozempic, Wegovy, Less Likely to Exercise Despite Benefits
Recent research has found that despite the benefits, people using GLP-1s may be less likely to exercise. Image Credit: Fiordaliso/Getty Images A recent study found that people taking a GLP-1 medication, like Ozempic or Wegovy, may be less likely to engage in regular exercise. The study showed that, among people with obesity, daily step count and moderate-to-vigorous activity duration decreased after starting GLP-1 medication. The greatest decline was seen in males and people with musculoskeletal pain. GLP-1 medications, like Ozempic, Wegovy, and Mounjaro, have become popular ways for people to lose weight and manage conditions like diabetes. A recent study found that people who begin using a GLP-1 medication appear to engage in less physical activity. However, evidence suggests that long-term weight management is most effective when combined with regular exercise. âThis study aligns with my clinical experience. I often find that patients feel more fatigued while losing weight, which can make exercise feel like a chore,â Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told Healthline. Ali wasnât involved in the study. This study is being presented at ENDO 2026, the Endocrine Societyâs annual meeting in Chicago, Illinois, and has not yet been published in a peer-reviewed journal. âWhile many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise,â Sajana Maharjan, MD, board certified internist at HSHS St. Johnâs Hospital in Springfield, IL, and lead author of the study, said in a press release. âThe findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity.â Why do people using GLP-1 medications exercise less? The study used data from the National Institutes of Health (NIH) All of Us Research Program.




